Drug intelligence / Profile preview

N-[(2S,4S,6R)-2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenylacetamide

Development stage
Unknown
Modality
Small Molecules
01

Overview

N-[(2S,4S,6R)-2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo- 4lambda~4~-thia- 1- azabicyclo[3.2.0]hept- 6- yl]-2- phenylacetamide is a synthetic compound classified as an experimental penicillin derivative and sometimes referred to as "oxidised penicillin G". It contains the core penam ring structure characteristic of the penicillins and is structurally related to beta-lactam antibiotics. The compound has been studied primarily for its interaction with the enzyme penicillin G acylase but does not have established clinical use or approved therapeutic indications[1][3][6]. Its mechanism of action would be expected to involve inhibition of bacterial cell wall synthesis via binding to and inactivating transpeptidase enzymes (penicillin-binding proteins), similar to other beta-lactams; however, this specific molecule appears mainly used in research contexts.

Other names
oxidised penicillin GSOXN-[2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-thiaazabicycloheptyl]-2-phenylacetamide
02

Targets

PNAG (Poly-N-acetylglucosamine)

Beyond the preview

Go deeper on N-[(2S,4S,6R)-2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenylacetamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-[(2S,4S,6R)-2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenylacetamide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call